CAMEL
Regimen
- Experimental
- camrelizumab + carbo + pem
- Control
- carbo + pem
Population
Chinese 1L non-sq NSCLC
Key finding
mPFS 11.3 vs 8.3 mo, HR 0.60 (0.45-0.79); camrelizumab 1L non-sq
Source: PMID 33347829
Timeline
- Enrollment start: 2017-05-12 📎
Guideline citations
- CSCO NSCLC 2025 ⚠️ OCR source